Zepbound

• 1/29/2025

  Cancer Breakthrough: Eli Lilly’s $533 Billion Opportunity

• 1/24/2025

  Medical Breakthroughs: The Dawn of a New Era

• 1/23/2025

  Is Eli Lilly’s Slump a Hidden Buying Opportunity?

• 1/19/2025

  Eli Lilly’s Revenue Outlook Shifts Amidst GLP-1RA Market Volatility

• 1/18/2025

  Eli Lilly’s Revenue Outlook Slumps Amidst Fierce Competition

• 1/16/2025

  Eli Lilly’s Q4 Revenue Guidance Falls Short, Shares Tumble 6%

• 1/16/2025

  Biotech Boom: 5 Trends to Watch in 2025

• 1/8/2025

  Weight Loss Showdown: Viking Therapeutics Faces Off Against Merck

• 12/28/2024

  Tirzepatide Access in Jeopardy: Patients Face Uncertain Future

• 12/26/2024

  Obesity Drug Setback Sparks Retail Rush into Novo Nordisk